What upadatinib does: How does it help treat rheumatoid arthritis, psoriasis and other immune diseases?

Upadacitinib is an oral Janus kinase (JAK) inhibitor that helps regulate the inflammatory response in the immune system by selectively inhibiting the JAK1 signaling pathway. The JAK pathway plays a key role in a variety of immune diseases. Therefore, inhibiting this pathway can reduce inflammation and tissue damage caused by immune responses. Upadatinib's mechanism of action makes it an important treatment option for rheumatoid arthritis (RA) and other immune diseases.

In the treatment of rheumatoid arthritis, upadatinib reduces joint inflammation and pain and improves joint function by suppressing overactive immune responses. Studies have shown that upadatinib can effectively slow down disease progression, reduce joint damage, and significantly improve patients' quality of life. It is particularly suitable for patients who do not respond well to traditional DMARDs (disease-modifying anti-rheumatic drugs) or biologics, providing more options as a new treatment option.

Upadatinib has also shown good efficacy in psoriasis, especially moderate to severe psoriasis. By inhibiting abnormal activation of the immune system, upadatinib can effectively reduce inflammation of the skin, reduce the formation of scales, and relieve symptoms such as itching. Clinical trials have shown that upadatinib can significantly improve the skin lesions of psoriasis patients, help patients restore normal skin function, and enhance their self-confidence and quality of life.

In addition, upadatinib is also used to treat other immune diseases, such as ulcerative colitis and ankylosing spondylitis. By modulating the immune system, upadatinib can reduce inflammation, control disease activity, and prevent further progression of the condition. Its efficacy and safety make it one of the treatment options for a variety of immune-mediated diseases, providing new hope especially for some patients for whom traditional treatments are unsatisfactory.

Reference materials:https://www.rinvoq.com/